Clinical Observation of E_2 Transdermal Patch in the Treatment of Menopaus-al Syndrome
- VernacularTitle:半水合雌二醇贴剂治疗绝经期症状的临床观察
- Author:
Qi YU
;
Xin GUO
;
Yiwen ZHANG
- Publication Type:Journal Article
- Keywords:
Symptom of menopause;
Estrogen;
Hormone threapy
- From:
Journal of Practical Obstetrics and Gynecology
2010;26(2):107-110
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the security, efficacy and side effects of E_2 transdermal patch (Fem-7) in the treatment of menopausal syndrome. Methods:A total of 60 cases with menopausal syndrome (blood serum FSH >30 U/L,E_2 <109.8 pmol/L) were randomly divided into treatment group ( Fem-7 group) and control group (estrodiol valerate (E_2V) group) for 12 weeks treatment. Fem-7 group changed patch every 7 days and took the 2 mg medroxyprogesterone (MPA) every day. While the E_2V group took the 2 mg MPA and 1.5 mg E_2 V every day. Serum E_2, FSH, lipoprotein and coagulation function were evaluated at baseline and at the 12th week of the treatment. In addition, menopausal symptoms and some other index of security and side effects were also observed. Results:Kupperman indix in both groups was decreased and the mean value of E_2 was increased obviously. Hepatic function, renal function, coagulation function and blood glucose were no obvious change. Lipoproteina was descended markedly in Fem-7 group. Other index of security in both groups was no obvious change. Conclusions:Fem-7 patch is secure and valid for relieving symptom of menopause, especially for the women who is not sutable for oral medication.
